Efficacy and safety of Ixazomib-based maintenance therapy after autologous hematopoietic stem cell transplantation in multiple myeloma patients: a retrospective analysis

Within the constraints of the current Chinese clinical context, ixazomib-based maintenance therapy demonstrates favorable efficacy and a manageable safety profile for MM patients after ASCT, offering a viable and accessible alternative. Achieving sustained MRD negativity is critically important for long-term outcomes, reinforcing its value as a key treatment goal. These real-world findings support the role of ixazomib, particularly for patients ineligible for or intolerant to standard regimens.